https://investors.modernatx.com/news/news-details/2023/Moderna-and-Merck-Announce-mRNA-4157-V940-an-Investigational-Individualized-Neoantigen-Therapy-in-Combination-with-KEYTRUDAR-Pembrolizumab-Demonstrated-Superior-Recurrence-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-Following-Comple/default.aspx
0
0
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano - Moderna Investor Relations
4/16/23 at 3:01pm
Organization
Modernatx.com
Authors
Details
78 words
Summarize
Business & Industrial Pharmaceuticals & Biotech Pharmacy Cancer Merck Announce mRNA-4157 Keytruda V940 Moderna Demonstrated Superior Recurrence High-Risk Stage III/IV Melano mRNA-4157 III/IV
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial sel…
Create an account or login to join the discussion